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Professor Sharona Hoffman is one of our most prominent health law scholars. She is particularly interested in the
intricacies of health privacy and quality in the context of pervasive healthcare technologies such as eltronic _heal th
rerds and big-data. Her expertise extends to a deep understanding of the Genetic Information Nondiscriminatio Act
of 20L8 (GINA) and the scope of the Americans with Disabilities Act (ADA). In her excellent article, What Genetic
Testing Teaches about Predictive Health Analytics Regulation, Hoffman neatly combines these interests, providing a
thoughtful critique of predictive health analytics founded on a detailed description of our legal and policy experiences
with genetic testing. The comparison is particularly pertinent because, to an extent, algorithmic medicine is stepping
into a space that many had hoped would by now be occupied by precision medicine.
Hoffman identifies the policy and regulatory issues raised by both genetic testing and what she labels as long-term
predictive analytics as "clinical validity and accuracy, privacy and discrimination, and psychological harms." (P. 14.) At
root, these raise the question of what Jessica Roberts and Elizabeth Weeks call "healthism," "[p]ermitting-and even
encouraging-discriminatory treatment based on an individual's health status."
Hoffman's position is that, while we have taken a "relatively cautious approach to genetic testing," the approach to
predictive health analytics has been "more cavalier." (P. 3.) To a large extent this is likely because the publicly-funded
human genome project featured (as Hoffman notes) a concomitant Ethical. Legal and Social Implications Research
Pogramn (ELSI). In contrast (and at least in the U.S.), most predictive health analytics projects are in the hands of
private actors such as Alphabet's Verily or IBM Watson (even if some of their products eventually may receive
reimbursement from public funds). A lack of social inquiry or concern with regard to the latter also may be attributable
to different media and public perceptions. Cracking our genetic code was big news, regularly reported on. In contrast,
analysis of predictive health analytics, while of interest to economists is more likely to be subsumed under broader,
frequently dystopian visions about the very future of mankind or at least its impact n employmen.
Hoffman correctly views the risks such as breach of privacy or discrimination associated with health analytics as
amplified by the inclusion of non-traditional data sources and the products such as health scores offered by businesses
such as data-brokers. Those observations also inform the regulatory problems she identifies. For example, while GINA
would regulate many of these activities if they involved genetic information the same cannot be said of predictive health
analytics. Similarly, as Hoffman points out, other regulatory models struggle here. Thus, the HIPAA Privacy Rule falls
down when data is in the hands of persons who are not covered entities or their business associates while the Food
and Drug Administration's jurisdiction maps poorly to these products and the risks they pose (notwithstanding the
agency's recent discussion paper on healthcare Al).
As a result and as Hoffman terms it, this "article is a call to action." (P. 32.) First, she argues that the scientific
community must "carefully consider the benefits and risks of predictive health analytics and implement safeguards to
address its hazards... and develop oversight mechanisms to safeguard the quality of predictive models." (P. 4.)
Second:
Data subjects should enjoy rights that give them a degree of control over their data including predicted health
outcomes. They should have an expanded right to consent to disclosure of their health information a right to
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discover who has seen their health data and a right to sue for privacy breaches that harm them and for
discrimination based on disease predictions.
(P. 4.) This second group of recommendations inevitably leads to a call for changes to the HIPAA rules and the ADA,
the former extending the reach of "covered entity" and "health information." Here I part company somewhat, as I
remain unconvinced that HIPAA can be usefully extended much beyond its current scope. I go further (accepting the
inevitable accusation of political naivety) arguing that when looking at regulatory options for healthcare Al we should go
big or go home.
Hoffman's "call to action" deserves immediate attention. So far the public debate in the U.S. has been muted, limited
to the technocratic musings of the Obama Administration's Artifiial Intelliaence Automation. and the Economy report to
the more jingoistic proposals of the Trump Administration' Artifical Inteligence for the American People. Our friends in
Europe seem be further along the regulatory path, benefiting from perceptive reports from both the HQuse Qf Lrds in
the UK and the European Commission's Ethics Guideines For Trustwrthy Al.
Professor Hoffman is on solid ground in arguing that now is the time for action. As she argues, "many more minds
must tackle the challenges of predictive health analytics and develop mechanisms to enhance the integrity and benefits
of this technology." (P. 39.) To do otherwise would be "imprudent and could cost society dearly." (P. 39.) Highlighting
those perils with her perceptive and apposite comparisons to the risks associated with genetic testing and the
appropriate legal and policy steps that followed will be the lasting message of this excellent article.
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